Different role of wave reflection magnitude and timing on left ventricular mass reduction during antihypertensive treatment

Journal of Hypertension

Volumn 26, Issue 5, 2008, Pages 1017-1024

  Hashimoto, Junichiro ^a   Westerhof, Berend E ^b   Westerhof, Nico ^b   Imai, Yutaka ^a   O'Rourke, Michael F ^c  

^a TOHOKU UNIVERSITY   (Japan)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antihypertensive treatment; Aorta; Arterial stiffness; Blood pressure; Heart; Pulse; Wave reflection

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AMPLITUDE MODULATION; AORTA PRESSURE; ARTICLE; BLOOD PRESSURE; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HEART STROKE VOLUME; HEART VENTRICLE PRESSURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT;

EID: 42049085072     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f62a9b     Document Type: Article

References (40)

1. Schneider MP, Klingbeil AU, Delles C, Ludwig M, Kolloch RE, Krekler M, et al. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension 2004; 44:61-66.
2. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
3. Nichols WW, O'Rourke MF. McDonald's blood flow in arteries. Theoretical, experimental and clinical principles, 5th ed. London: Hodder Arnold; 2005.
4. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275:1507-1513.
5. Bishop JE, Kiernan LA, Montgomery HE, Gohlke P, McEwan JR. Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. Cardiovasc Res 2000; 47:57-67.
6. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005; 18:3S-10S.
7. Nichols WW, Singh BM. Augmentation index as a measure of peripheral disease state. Curr Opin Cardiol 2002; 17:543-551.
8. Hashimoto J, Watabe D, Hatanaka R, Hanasawa T, Metoki H, Asayama K, et al. Enhanced radial late-systolic blood pressure augmentation in hypertensive patients with left ventricular hypertrophy. Am J Hypertens 2006; 19:27-32.
9. Lekakis JP, Zakopoulos NA, Protogerou AD, Kotsis VT, Papaioannou TG, Stamatelopoulos KS, et al. Cardiac hypertrophy in hypertension: relation to 24-h blood pressure profile and arterial stiffness. Int J Cardiol 2004; 97:29-33.
10. Marchais SJ, Guerin AP, Pannier BM, Levy BI, Safar ME, London GM. Wave reflections and cardiac hypertrophy in chronic uremia. Influence of body size. Hypertension 1993; 22:876-883.
11. Saba PS, Roman MJ, Pini R, Spitzer M, Ganau A, Devereux RB. Relation of arterial pressure waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol 1993; 22:1873-1880.
12. Sharman JE, Stowasser M, Fang ZY, Prins JB, Haluska B, Marwick TH. Left ventricular mass in patients with type 2 diabetes is independently associated with central but not peripheral pulse pressure. Diabetes Care 2004; 28:937-939.
13. DeLuca N, Asmar RG, London GM, O'Rourke MF, Safar ME. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004; 22:1623-1630.
14. Hashimoto J, Imai Y, O'Rourke MF. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. Am J Hypertens 2007; 20:378-384.
15. Davies JI, Struthers AD. Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses. J Hypertens 2003; 21:463-472.
16. Murgo JP, Westerhof N, Giolma JP, Altobelli SA. Aortic input impedance in normal man: relationship to pressure wave forms. Circulation 1980; 62:105-116.
17. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension 2004; 43:1239-1245.
18. Kelly RP, Millasseau SC, Ritter JM, Chowienczyk PJ. Vasoactive drugs influence aortic augmentation index independently of pulse wave velocity in healthy men. Hypertension 2001; 37:1429-1433.
19. London GM, Asmar RG, O'Rourke MF, Safar ME, On behalf of the REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43:92-99.
20. Stokes GS, Barin WS, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension 2003; 41:297-301.
21. Stewart AD, Millasseau SC, Kearney MT, Ritter JM, Chowienczyk PJ. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension 2003; 42:915-918.
22. Mitchell GF, Tardif JC, Arnold MO, Marchiori G, O'Brien TX, Dunlap ME, et al. Pulsatile hemodynamics in congestive heart failure. Hypertension 2001; 38:1433-1439.
23. Westerhof BE, Guelen I, Westerhof N, Karemaker JM, Avolio A. Quantification of wave reflection in the human aorta from pressure alone: a proof of principle. Hypertension 2006; 48:595-601.
24. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 2001; 53:189-192.
25. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
26. Hashimoto J, Chonan K, Aoki Y, Nishimura T, Ohkubo T, Hozawa A, et al. Pulse wave velocity and the second derivative of the finger photoplethysmogram in treated hypertensive patients: their relationship and associating factors. J Hypertens 2002; 20:2415-2422.
27. Karamanoglu M, O'Rourke MF, Avolio AP, Kelly RP. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. Eur Heart J 1993; 14:160-167.
28. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38:932-937.
29. O'Rourke MF, Pauca AL. Augmentation of the aortic and central arterial waveform. Blood Press Monit 2004; 9:179-185.
30. Murgo JP, Westerhof N, Giolma JP, Altobelli SA. Manipulation of ascending aortic pressure and flow wave reflections with the Valsalva maneuver: relationship to input impedance. Circulation 1981; 63:122-132.
31. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 58:1072-1083.
32. Devereux RB, James GD, Pickering TG. What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal or abnormal left ventricular geometry. Am J Hypertens 1993; 6:211S-215S.
33. Safar ME. Mechanisms of systolic blood pressure reduction and drug therapy in hypertension. Hypertension 2007; 50:167-171.
34. Asmar RG, London GM, O'Rourke MF, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38:922-926.
35. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
36. Westerhof N, O'Rourke MF. Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. J Hypertens 1995; 13:943-952.
37. Avolio AP, Deng FQ, Li WQ, Luo YF, Huang ZD, Xing LF, et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation 1985; 71:202-210.
38. Stewart AD, Jiang B, Millasseau SC, Ritter JM, Chowienczyk PJ. Acute reduction of blood pressure by nitroglycerin does not normalize large artery stiffness in essential hypertension. Hypertension 2006; 48:404-410.
39. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, et al. Improved arterial compliance by a novel advanced glycation endproduct crosslink breaker. Circulation 2001; 104:1464-1470.
40. Mitchell GF, Izzo JL, Lacourciere Y, Ouellet JP, Neutel J, Qian C, et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002; 105:2955-2961.